247 related articles for article (PubMed ID: 23588143)
21. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED
Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
[TBL] [Abstract][Full Text] [Related]
22. Adalimumab for the treatment of inflammatory bowel disease.
Wasan SK; Kane SV
Expert Rev Gastroenterol Hepatol; 2011 Dec; 5(6):679-84. PubMed ID: 22017695
[TBL] [Abstract][Full Text] [Related]
23. The safety and efficacy of antitumour necrosis factor-alpha therapy for inflammatory bowel disease in patients post liver transplantation: a case series.
Sandhu A; Alameel T; Dale CH; Levstik M; Chande N
Aliment Pharmacol Ther; 2012 Jul; 36(2):159-65. PubMed ID: 22616981
[TBL] [Abstract][Full Text] [Related]
24. Moving towards disease modification in inflammatory bowel disease therapy.
Allen PB; Peyrin-Biroulet L
Curr Opin Gastroenterol; 2013 Jul; 29(4):397-404. PubMed ID: 23695427
[TBL] [Abstract][Full Text] [Related]
25. Extra-Gastrointestinal Manifestations of Inflammatory Bowel Disease May Be Less Common Than Previously Reported.
Card TR; Langan SM; Chu TP
Dig Dis Sci; 2016 Sep; 61(9):2619-26. PubMed ID: 27193564
[TBL] [Abstract][Full Text] [Related]
26. Skin Manifestations of Inflammatory Bowel Disease.
Greuter T; Navarini A; Vavricka SR
Clin Rev Allergy Immunol; 2017 Dec; 53(3):413-427. PubMed ID: 28643285
[TBL] [Abstract][Full Text] [Related]
27. Ustekinumab for Extra-intestinal Manifestations of Inflammatory Bowel Disease: A Systematic Literature Review.
Guillo L; D'Amico F; Danese S; Peyrin-Biroulet L
J Crohns Colitis; 2021 Jul; 15(7):1236-1243. PubMed ID: 33367674
[TBL] [Abstract][Full Text] [Related]
28. Associated comorbidities in psoriasis and inflammatory bowel disease.
Binus AM; Han J; Qamar AA; Mody EA; Holt EW; Qureshi AA
J Eur Acad Dermatol Venereol; 2012 May; 26(5):644-50. PubMed ID: 21689167
[TBL] [Abstract][Full Text] [Related]
29. [Immune-Mediated Inflammatory Diseases and accompanying comorbidities].
Majdan M
Wiad Lek; 2016; 69(4):611-615. PubMed ID: 27941197
[TBL] [Abstract][Full Text] [Related]
30. Significance of erythema nodosum and pyoderma gangrenosum in inflammatory bowel diseases: a cohort study of 2402 patients.
Farhi D; Cosnes J; Zizi N; Chosidow O; Seksik P; Beaugerie L; Aractingi S; Khosrotehrani K
Medicine (Baltimore); 2008 Sep; 87(5):281-293. PubMed ID: 18794711
[TBL] [Abstract][Full Text] [Related]
31. Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents.
Gao X; Wendling D; Botteman MF; Carter JA; Rao S; Cifaldi M
J Med Econ; 2012; 15(6):1054-63. PubMed ID: 22563743
[TBL] [Abstract][Full Text] [Related]
32. The concept of psoriatic disease: can cutaneous psoriasis any longer be separated by the systemic comorbidities?
Lotti T; Hercogova J; Prignano F
Dermatol Ther; 2010; 23(2):119-22. PubMed ID: 20415818
[TBL] [Abstract][Full Text] [Related]
33. Association of psoriasis/psoriatic arthritis with inflammatory bowel disease influences management strategy.
Shaw CA; Kole LCS; Elewski BE
J Eur Acad Dermatol Venereol; 2019 Nov; 33(11):e431-e432. PubMed ID: 31220373
[No Abstract] [Full Text] [Related]
34. Anti-TNF agents for the treatment of psoriasis.
Kircik LH; Del Rosso JQ
J Drugs Dermatol; 2009 Jun; 8(6):546-59. PubMed ID: 19537380
[TBL] [Abstract][Full Text] [Related]
35. Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical setting.
Navarro R; Vilarrasa E; Herranz P; Puig L; Bordas X; Carrascosa JM; Taberner R; Ferrán M; García-Bustinduy M; Romero-Maté A; Pedragosa R; García-Diez A; Daudén E
Br J Dermatol; 2013 Mar; 168(3):609-16. PubMed ID: 22985451
[TBL] [Abstract][Full Text] [Related]
36. [Application of TNF-alpha blocker concentration assays in the treatment of inflammatory bowel diseases].
Sipponen T; Kolho KL
Duodecim; 2013; 129(5):499-505. PubMed ID: 23520893
[TBL] [Abstract][Full Text] [Related]
37. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study.
Bernstein CN; Blanchard JF; Rawsthorne P; Yu N
Am J Gastroenterol; 2001 Apr; 96(4):1116-22. PubMed ID: 11316157
[TBL] [Abstract][Full Text] [Related]
38. Dermatological signs during inflammatory bowel diseases.
Feliciani C; De Simone C; Amerio P
Eur Rev Med Pharmacol Sci; 2009 Mar; 13 Suppl 1():15-21. PubMed ID: 19530507
[TBL] [Abstract][Full Text] [Related]
39. Sequential use of biologics in the treatment of moderate-to-severe plaque psoriasis.
Leman J; Burden AD
Br J Dermatol; 2012 Nov; 167 Suppl 3():12-20. PubMed ID: 23082811
[TBL] [Abstract][Full Text] [Related]
40. Inflammatory arthritis following ustekinumab treatment for psoriasis: a report of two cases.
de Souza A; Ali-Shaw T; Reddy SM; Fiorentino D; Strober BE
Br J Dermatol; 2013 Jan; 168(1):210-2. PubMed ID: 23278559
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
